Demegen Overview
- Founded
-
1992
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
4
- Investments
-
1
Demegen General Information
Description
Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fungi. The company develops products for the treatment of dermatological, vaginal, respiratory, ophthalmic and oral diseases with the peptides bind to and kill harmful microorganisms.
Contact Information
Website
www.demegen.com
Formerly Known As
Demeter BioTechnologies
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Par Advance Technologies
Primary Office
- 100 Technology Drive
- Suite 440B
- Pittsburgh, PA 15219
- United States
Demegen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Demegen Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fun
Biotechnology
Pittsburgh, PA
000
000000&0
000
000000
ation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderi
0000000000000
Salt Lake City, UT
0000
As of 0000
00000
000000 - 000
00000
000000
lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000000000000
Aurora, CO
0
As of 0000
0000000000
Add Comparison
Demegen Competitors (4)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Myriad Genetics | Corporation | Salt Lake City, UT | 0000 | 00000 | 000000 - 000 | 00000 |
| 00000000000 | Corporation | Aurora, CO | 0 | 0000000000 | ||
| 00000000 000000000 | Venture Capital-Backed | Wuxi, China | 00000 | 00000000000 | 00000 | |
| 0000000 0000000000 | Venture Capital-Backed | Pensacola, FL | 00 | 00000 | 00000000000 | 00000 |
Demegen Patents
Demegen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20020022048-A1 | Bioerosable film; adhesion to mucous membranes | Abandoned | 26-May-2000 | 000000000 | 0 |
| EP-1328234-A1 | Methods for treating cystic fibrosis | Withdrawn | 08-Jan-1999 | 00000000000 | |
| AU-3344500-A | Methods for treating cystic fibrosis | Abandoned | 08-Jan-1999 | 00000000000 | |
| US-6528488-B2 | Therapy of cystic fibrosis in a mammal by administering mammal an effective amount of a histatin or its fragment | Expired - Lifetime | 08-Jan-1999 | 00000000000 | 0 |
| US-20020077282-A1 | Therapy of cystic fibrosis in a mammal by administering mammal an effective amount of a histatin or its fragment | Granted | 08-Jan-1999 | C07K14/4723 |
Demegen Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Richard Ekstrom | Chief Executive Officer |
Demegen Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Demegen Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000000 | 01-Jan-2001 | 0000000000 | Other Pharmaceuticals and Biotechnology |